Navigation Links
Cardium's InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
Date:7/15/2009

SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) ("Cardium") today announced that it has entered into a definitive Asset Purchase Agreement for the acquisition of Cardium's InnerCool Therapies business ("InnerCool") by Royal Philips Electronics (NYSE: PHG, AEX: PHI). The asset purchase transaction for $11.25 million, as well as the transfer of approximately $1.5 million in trade payables, is subject to customary closing conditions but is expected to close shortly. Once this transaction is complete the InnerCool business will operate within Philips' Healthcare sector.

(Logo:http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"The acquisition of InnerCool by Philips represents an important step forward in Cardium's overall business strategy which is focused on the acquisition, strategic repositioning and partnering or sale of businesses within our bio-medical investment portfolio. With a substantially reduced cost structure, the proceeds from this transaction will be used to enhance Cardium's balance sheet and for working capital to support the further development of Cardium's biomedical investment portfolio and product development pipeline, particularly its Excellarate(TM) Tissue Repair product candidate, which recently completed enrollment for a key clinical study," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies. "We have made significant progress in developing best-in-class products and a portfolio of innovative product opportunities, and we will continue to seek additional partnering
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
2. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
3. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
4. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
5. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
8. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
9. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
10. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
11. AACR 100th Annual Meeting Highlights Superior Ability of InNexus DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for ... advancing knowledge and research in reproductive medicine. In ... a seat on the executive board and will have ... , Dr. Hill has actively supported ASRM since 1984 ...
(Date:12/24/2014)... , December 23, 2014 ... Algeria , out today and available for free download ... actors driving change and growth in the sector today. ... scored notable successes has been in developing a homegrown pharmaceutical ... percent local production still remains some way off. A cursory ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Colo., Oct. 9 Replidyne, Inc.,(Nasdaq: RDYN ) ... and,webcast on Tuesday, October 30, 2007 at 4:45 P.M. ... in the conference call by,dialing 800-435-1261 (domestic) or 617-614-4076 ... the conference call will be available approximately one,hour after ...
... of Clinical Programs, PALO ALTO, Calif., Oct. ... a late-stage biotechnology company that,develops central nervous system ... be a presenting company at the 4th,Annual BIO ... at the,Palace Hotel of San Francisco. The company,s ...
... Oct. 8 Inverness Medical,Innovations (Amex: IMA ) ... Agreement with Panbio Ltd, an Australian company traded on,the ... will acquire all of the issued shares in Panbio ... values the issued share capital of,Panbio at approximately AUD ...
Cached Biology Technology:Replidyne to Announce Third Quarter 2007 Earnings 2Avicena to Present at 4th Annual BIO InvestorForum Conference 2Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... common adult leukemia in the United States was last reviewed ... it was seen through the eyes of theories that dated ... three of the world's foremost experts on chronic lymphocytic leukemia ... the scientific community's knowledge of CLL that has occurred over ...
... TechTransfer,recently licensed software that will give scientists ... software, known as Rosetta, predicts how proteins ... and biomedical researchers.,UW Tech Transfer's Digital Ventures ... for Systems Biology (ISB), a non-profit,research organization. ...
... stem cells found in the skin hints at a new ... the University of Pennsylvania School of Medicine. These genes ?dubbed ... a hold on future differentiation until the time is right. ... therapies that involve tissue regeneration. , The researchers found that ...
Cached Biology News:Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine 2UW's Rosetta software to unlock secrets of many human proteins 2Newly-discovered class of genes determines ?and restricts ?stem cell fate 2
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
DTT, 25g...
...
Biology Products: